Related Experiment Video
Updated: Aug 30, 2025
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
40.8K
Effectiveness of a Digital Inhaler System for Patients With Asthma: A 12-Week, Open-Label, Randomized Study
Flavia C L Hoyte1, Giselle S Mosnaim2, Linda Rogers3
1Division of Allergy/Immunology, Department of Medicine, National Jewish Health, Denver, University of Colorado Hospital, Aurora, Colo.
The Journal of Allergy and Clinical Immunology. in Practice
|August 29, 2022
Summary
The Reliever Digihaler System (RDS) showed an 85.3% probability of improving asthma control compared to standard care. This digital health tool aids in managing asthma by tracking inhaler usage and inhalation quality.
Area of Science:
- Digital health interventions in respiratory medicine.
- Asthma management and control strategies.
- Wearable technology for chronic disease monitoring.
Background:
- The Reliever Digihaler System (RDS) integrates a smart albuterol inhaler with a digital platform to monitor usage and inhalation quality.
- This system facilitates data review for patients and healthcare providers to inform clinical decisions.
Purpose of the Study:
- To assess the effectiveness of the RDS in improving asthma control compared to standard care.
- To evaluate changes in asthma control as measured by the Asthma Control Test (ACT) score.
Main Methods:
- A 12-week randomized study involving participants aged 13+ with suboptimal asthma control (ACT < 19).
- Participants were assigned to either the RDS or standard albuterol inhaler (SoC).
- Bayesian statistical analysis was used to compare outcomes, focusing on clinically meaningful improvements in asthma control.
Main Results:
- Participants using the RDS demonstrated an 85.3% probability of achieving greater odds of clinically meaningful asthma control improvement versus SoC.
- The mean odds ratio for improvement was 1.33 (95% credible interval: 0.813-2.050) after 3 months.
Conclusions:
- The RDS showed a higher likelihood of leading to clinically meaningful improvements in asthma control over 3 months compared to standard care.
- Further research is recommended to explore the full potential of the RDS in enhancing asthma management.
Related Concept Videos
01:23Inhaled Medications
370
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
370
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
371
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
371
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
351
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
351
01:30Asthma-IV: Nursing Management
3.3K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
3.3K
01:26COPD: Management Using Bronchodilators and Corticosteroids
283
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
283